Kost K, Singh S, Vaughan B, et al. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception. 2008;77:10–21.
Huber LR, Hogue CJ, Stein AD, et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation, and choice study. Am J Obstet Gynecol. 2006;194:1290–1295.
Skouby SO., Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care. 2004;9:57–68.
Bitzer J, Paoletti AM., Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin Drug Investig. 2009;29:73–78.
Coelingh Bennink HJT, Foidart JM., Estetrol, a fetal steroid for the treatment of adults. J Reprod Med Endokrinol Online. 2015;12:399–403.
Duijkers IJ, Klipping C, Zimmerman Y, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study. Eur J Contracept Reprod Health Care. 2015;20:476–489.
Mawet M, Maillard C, Klipping C, et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Health Care. 2015;20:463–475.
Kluft C, Zimmerman Y, Mawet M, et al. Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol. Contraception. 2017;95:140–147.
Apter D, Zimmerman Y, Beekman L, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016;94:366–373.
World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Geneva, Switzerland: WHO Press; 2009. p. 15–44.
Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
Perez-Campos E, Duenas JL, de la Viuda E, et al. Development and validation of the SEC-QOL questionnaire in women using contraceptive methods. Value Health. 2011;14:892–899.
Egarter C, Topcuoglu MA, Imhof M, et al. Low dose oral contraceptives and quality of life. Contraception. 1999;59:287–291.
Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124–134.
Agresti A., An introduction to categorical data analysis. 2nd ed. Wiley-Interscience; 2007.
Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med. 2011;8:2841–2850.
Davis SR, Bitzer J, Giraldi A, et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med. 2013;10:3069–3079.
Nappi RE, Serrani M, Jensen JT., Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health. 2014;6:711–718.
Lete I, de la Viuda E, Perez-Campos E, et al. Effect on quality of life of switching to combined oral contraception based on natural estrogen: an observational, multicentre, prospective phase IV study (ZOCAL Study). Eur J Contracept Reprod Health Care. 2016;21:276–284.
Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37–51.
Foidart JM., Added benefits of drospirenone for compliance. Climacteric. 2005;8(Suppl. 3):28–34.
Kelly S, Davies E, Fearns S, et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study. Clin Drug Investig. 2010;30:325–336.
Ciaplinskiene L, Zilaitiene B, Verkauskiene R, et al. The effect of a drospirenone-containing combined oral contraceptive on female sexual function: a prospective randomised study. Eur J Contracept Reprod Health Care. 2016;21:395–400.
Palacios S, Wildt L, Parke S, et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a phase III trial. Eur J Obstet Gynecol Reprod Biol. 2010;149:57–62.
Bagwell MA, Thompson SJ, Addy CL, et al. Primary infertility and oral contraceptive steroid use. Fertil Steril. 1995;63:1161–1166.
Chasan-Taber L, Willett WC, Stampfer MJ, et al. Oral contraceptives and ovulatory causes of delayed fertility. Am J Epidemiol. 1997;146:258–265.
Di Carlo C, Gargano V, De Rosa N, et al. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age. Gynecol Endocrinol. 2014;30:925–928.